What a Methadone–Buprenorphine Trial Can Establish About Stimulant Co-Use
A comparison of opioid treatments can examine stimulant co-use without showing that either treatment is an established methamphetamine intervention. A Canadian analysis illustrates why the comparison and its confidence interval matter.
The study compared models of care
Langlois and colleagues analyzed a 24-week pragmatic trial comparing supervised methadone with flexible take-home buprenorphine/naloxone care. The analysis included 210 participants who initiated opioid agonist therapy; 130 had methamphetamine/amphetamine use at baseline.
Use was assessed with urine testing and self-report. The study’s combined methamphetamine/amphetamine category should not be silently relabeled as an exclusively methamphetamine-specific endpoint.
No clear treatment difference was established
The adjusted treatment comparison yielded an odds ratio of 0.61 with a 95% confidence interval of 0.34–1.08. The interval included the no-difference value of 1. The time-in-treatment comparison and treatment-by-time interaction also were not statistically significant.
A point estimate below 1 can motivate further investigation. It does not establish superiority when the uncertainty includes no difference, and a nonsignificant finding does not establish exact equivalence.
Preserve the actual treatment context
The comparison involved medication and delivery arrangements. It should not be treated as a laboratory experiment that isolates a single pharmacological effect from every feature of supervised versus take-home care.
These results concern people initiating care for opioid use disorder. They neither justify withdrawing opioid treatment because of stimulant use nor determine the expected course of an individual patient.
Scientific source
Langlois J and colleagues. Comparative Effectiveness of Buprenorphine/Naloxone and Methadone on Methamphetamine/Amphetamine Use Among People with Opioid Use Disorder in Canada. Substance Use & Addiction Journal. 2025;46:518–530. doi:10.1177/29767342241298044. Based on the supplied trial analysis.



